Anti-Infective Endotracheal Tube Market Size and Trends

Global anti-infective endotracheal tube market is estimated to be valued at USD 850 Mn in 2024 and is expected to reach USD 1,200 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5% from 2024 to 2031.

Anti-Infective Endotracheal Tube Market Key Factors

To learn more about this report, request sample copy

Increasing incidence of hospital-associated infections and rising demand for advanced medical devices to curb the risk of infection can drive the market growth. Rising number of surgical procedures performed worldwide and growing geriatric population who are prone to chronic diseases and requires ventilation support can also boost the usage of anti-infective endotracheal tubes. However, availability of alternative intubation and ventilation methods and lack of awareness regarding benefits of anti-infective endotracheal tubes in developing countries can hamper the market growth over the forecast period.

Market Driver - Growing prevalence of respiratory diseases

With changing lifestyle and rising pollution levels, there has been increase in incidence of respiratory diseases globally. Chronic respiratory conditions like asthma and COPD have become quite common, owing to rising air pollution and tobacco consumption. According to some estimates, over 235 million people suffer from asthma and prevalence has increased by over 50% in the last 25 years. These chronic respiratory diseases often require hospitalization when condition deteriorates and exacerbate.

Seasonal infections like pneumonia and influenza continue to plague people of all age groups but has higher impact on aged population and children. Such lower respiratory tract infections can sometimes turn critical, requiring mechanical ventilation support through endotracheal intubation. According to WHO, lower respiratory infections are one of the top five causes of deaths worldwide. These can lead to acute respiratory failure needing respiratory support through artificial airways like endotracheal tubes in some severe cases.

With growing global pollution levels due to rapid urbanization and industrialization, there has been increase in cases of respiratory diseases, thus, imposing greater disease burden. This can boost demand for respiratory support equipment including anti-infective endotracheal tubes, which can help lower the risks of ventilator-associated pneumonia. The tube is inserted with an inflated cuff that reduces leakage of oral and gastric secretions into the lungs to minimally support hospital-acquired infections in critically ill patients. Thus, surging prevalence of chronic and acute respiratory infections boosts need for effective ventilation strategies and drive the anti-infective endotracheal tube market growth.For Instance, According to article published in The Indian Express [P] Ltd. A recent study conducted by MSRC & Group, a healthcare research and consulting organization, has revealed that Chronic Obstructive Pulmonary Disease (COPD) is one of the fastest-growing respiratory diseases in India. The study, based on a 15-year prescription audit involving over 10,700 doctors across 80 cities and towns, found that respiratory diseases now represent the largest disease area in the country, accounting for 15.3% of all prescriptions.

Increasing number of intensive care unit admissions

Rise in population vulnerability to health deteriorations, availability of improved critical care facilities and aging populations contribute to increasing ICU admissions in hospitals worldwide. ICUs commonly treat patients suffering major trauma injuries, undergoing complex surgeries or battling life-threatening illnesses. Vast majority of patients in ICUs require ventilation support due to respiratory failure, which involves endotracheal intubation. As per some estimates, over 4 million patients are admitted to ICUs annually in the United States. With improving access to healthcare services in developing nations, the global ICU caseload has seen consistent expansion over the past decade.

Prolonged ventilation further increases the threat of hospital-acquired lung infections like ventilator-associated pneumonia. It is one of the most prevalent healthcare-associated infections accounting for over 25% of total HAI burden. Around 10% of all hospitalized patients get into the ICU at some point, thus, it is important to reduce infection rates. Hence, hospitals are increasingly employing anti-infective endotracheal tubes as these significantly reduce VAP occurrence and help ICUs adhere to stringent patient safety and hygiene guidelines.